

Global Harmonization Task Force

Proposed Document

Title: Guidelines for Regulatory Auditing of Quality

Management Systems of Medical Device

Manufacturers –

Part 3: Regulatory Audit Reports

Authoring Group: GHTF Study Group 4: Auditing

Date: 27 June 2006

Document number: SG 4/N33 R13	& Title: Guidelines for Regulatory auditing of Quality management Systems of
	Medical Device Manufacturers – Part 3: Regulatory Audit Repor

Submitted by (name):_____ Affiliated to: _____ On: <u>dd/mm/yyyy</u>

Comment Number	Affiliation (e.g. FDA)	Page / Section / Line	Editorial or Technical	Comment and rationale	Proposed revised text	SG Decision (& date)
1						
2						
3						
4						
5						
6						

Part 3: Regulatory Audit Report SG4 (PD1) N33 R13 – Study Group 4 – Proposed Document

1		Table	of Contents	
2				
3		Preface		
4	1.0	Introdu	ction	
5	2.0	Scope		
6	3.0	Purpose		
7	4.0	Rationale		
8	5.0	References		
9	6.0	Definitions		
10				
11	7.0	_	ves and User Needs of a Regulatory Audit Report	
12		7.1	Audit report objectives	
13		7.2	User needs for the auditing organization/regulatory authority	
14		7.3	User needs for the designating authority that oversees the auditing	
15			organizations	
16		7.4	User needs for the manufacturer and/or auditee	
17				
18	8.0	Main p	oints of an Audit report	
19		8.1	Data concerning auditee	
20		8.2	Data concerning audit	
21		8.3	Audit trail	
22			Conclusion	
23		8.5	Signature and dating of report	
24		8.6	Attachments	
25				
26	Attach	ched: History File		

27 June 2006 Seite 3 von 12

Part 3: Regulatory Audit Report SG4 (PD1) N33 R13 - Study Group 4 - Proposed Document

Preface

2 3

4

5

1

This document was produced by the Global Harmonization Task Force, a voluntary group of representatives from medical device regulatory agencies and the regulated industry. The document is intended to provide nonbinding guidance for use in the regulation of medical devices, and has been subject to consultation throughout its development.

6 7 8

9

10

There are no restrictions on the reproduction, distribution or use of this document; however, incorporation of this document, in part or in whole, into any other document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the Global Harmonization Task Force.

11 12 13

1. Introduction

14 15 16

This document gives guidance to regulators, auditing organizations and auditors on the content of audit reports. However, it may also help the auditee understand and respond to the audit findings.

18 19 20

17

Potential benefits for the regulators and auditing organizations include:

21 22 Greater consistency in audit reports both among auditors within an auditing organization and between auditing organizations

23 Greater collaboration between regulators/auditing organizations in regard to 24

regulatory audits Increased confidence in audits performed by an auditing organization and

26 27

acceptance of those audits by other regulators Saving resources

28

Guidance for countries developing medical device regulatory systems.

29 30

25

Potential benefits for the manufacturer of medical devices include:

- 31 Improved communication that results in improved quality management systems and 32 product quality 33
 - Greater consistency in audit reports
 - Reducing the number of times a single manufacturer undergoes audits
 - Saving resources •
 - Increased confidence in, and acceptability of, audit reports.

36 37 38

39

40

34

35

This document has been prepared by GHTF Study Group 4 "Regulatory Auditing". Comments or questions about the use of this guidance document should be directed to the Chair of SG 4 whose contact details may be found on the GHTF web page (www.ghtf.org).

41 42

> 27 June 2006 Seite 4 von 12

Part 3: Regulatory Audit Report SG4 (PD1) N33 R13 – Study Group 4 – Proposed Document

2.0 Scope

This document is intended to be used by regulators and auditing organizations as a guide for writing a report of a regulatory medical device quality management system audit. Such audits will be based on the process approach to quality management system requirements (e.g. ISO 13485:2003 and 21 CFR Part 820). This is described in "Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers, Part 2: Regulatory Auditing Strategy".

It may be necessary to address additional regulatory requirements to meet the needs of the regulators receiving and using the audit report.

The level of detail in the audit report will vary according to its likely use. This guideline describes a report which can be exchanged with other regulatory or auditing organizations with which the auditing organization has a formal relationship concerning confidentiality.

3.0 Purpose

 The purposes of this document are to harmonize the content of audit reports and to provide guidance on best practices for reporting audit results

4.0 Rationale

This guideline promotes consistency in audit reports – important in harmonization and mutual acceptance of audit results.

The audit report should demonstrate that quality management system and regulatory requirements have been covered and that the audit was sufficiently thorough and complete.

This guideline will provide a structure for audit reports used in multiple jurisdictions, promoting consistency and uniformity and will assist the auditor in preparing a report for use by multiple regulators and/or auditing organizations. Having reports that are consistent in content will facilitate the review and exchange of audit reports. Acceptance of audit reports by multiple regulators should eventually reduce the number of audits for manufacturers.

This document can also be used in support of bilateral agreements.

27 June 2006 Seite 5 von 12

Part 3: Regulatory Audit Report SG4 (PD1) N33 R13 – Study Group 4 – Proposed Document

5.0 References for applicable documents

GHTF/SG4/N28R2: Guidelines for Regulatory Auditing of Quality Systems of
 Medical Device Manufacturers – Part 1: General Requirements (1999)

GHTF/SG4/N30R18: Guidelines for Regulatory Auditing of Quality management systems of Medical Device Manufacturers – Part 2: Regulatory Auditing Strategy (final document 16 February 2006)

GHTF/SG2/N36R7: Manufacturer's Trend Reporting of Adverse Events

US FDA 21 CFR Part 820 – Quality System Regulation (October 7, 1996, Federal Register 61 FR 52602)

ISO 9000:2005: Quality Management Systems – Fundamentals and Vocabulary ISO 13485:2003: Medical devices – Quality Management Systems - Requirements for Regulatory Purposes

ISO 19011:2002: Guideline for Quality and/or Environmental Management Systems Auditing

6.0 Definitions

Adverse event:

An "Adverse Event" is either a malfunction or a deterioration in the characteristics or performance of a sold medical device [including accessory(s) and labelling] or use error, which either has caused or could have caused or contributed to death, or serious injury to health of patients or other persons.

29 (GHTF SG 2/N36R7)

Audit findings

Results of the evaluation of the collected audit evidence against audit criteria

Note: Audit findings can indicate either conformity or nonconformity with audit criteria or opportunities for improvement

(ISO 19011:2002)

Compliance / Conformity

Fulfilment of regulatory requirements

Note: In this document the terms "compliance" and "conformity" are used interchangeably whereas in some jurisdictions they may have distinct and different meanings.

27 June 2006 Seite 6 von 12

Part 3: Regulatory Audit Report

SG4 (PD1) N33 R13 – Study Group 4 – Proposed Document

1 Critical supplier

A critical supplier is a supplier delivering materials, components, services, which may influence the safety and performance of the product.

3 4 5

6

7

2

Designating Authority (DA)

Body established within government or empowered by government to designate auditing organizations, suspend or withdraw their designation or remove their suspension from designation.

8

10 Nonconformity

- 11 Nonfulfilment of a requirement
- 12 (ISO 9000:2005)

Note: For explanation of the term "major nonconformity" see SG4N28

13 14 15

Regulatory audit:

- The audit of a quality management system to demonstrate conformity with quality management system requirements for regulatory purposes.
- **Note:** For the purpose of these guidelines, "audit" means a regulatory audit.
- 19 (GHTF SG 4 N 30)

20 21

22

23

24

Regulatory audit report

The regulatory audit report is a document or set of documents from the regulatory audit team containing administrative data, a summary of the locations, functions or processes that were audited, audit findings and conclusions.

Note: For the purpose of these guidelines, "audit report" means a regulatory audit report

252627

28

29

Regulatory requirements

- Any part of a law, ordinance, decree, or other regulation which applies to medical device manufacturers.
- Note 1: Guidelines, draft documents or the like should not be used as regulatory
- 31 documents and should not be construed as such unless formally promulgated.
- 32 (GHTF SG 4 N 28)

Note 2:For the purpose of this guidance regulatory requirements are restricted to those pertaining to the quality management system.

35 36

33

34

7.0 Objectives and User Needs of an Audit report

38 39

37

7.1 Audit report objectives

40 41

The audit report comprises the documented evidence of a regulatory audit. It should contain sufficient information:

42 43

27 June 2006 Seite 7 von 12

Part 3: Regulatory Audit Report

SG4 (PD1) N33 R13 - Study Group 4 - Proposed Document

- To document the type of audit, the audit criteria, what was covered during the audit,
 and the audit findings
 - To evaluate the auditee's compliance status and effectiveness of the implementation of the quality management system and draw audit conclusions
 - To allow the exchange of audit reports between regulators and/or auditing organizations

6 7 8

3

4

5

7.2 User needs for the auditing organization/regulator

9

- 10 The auditing organization/regulators may use audit reports for the following:
- To provide a record of the auditing activities
- To evaluate the auditee's compliance with regulatory requirements
- To provide evidence for a regulatory decision
- To prepare for the next audit
- To provide an audit history
- To trend compliance history for the auditee
- To trend compliance for the industry
- To follow up on adverse event reports
- To exchange information between auditing organizations/regulators
- To evaluate the performance of the auditor(s)
 - To improve consistency between auditors

21 22 23

7.3 User needs for the designating authority that oversees the auditing organizations

24 25

26

27

28

- The designating authority that oversees the auditing bodies uses audit reports:
- To assess the competence of the auditing organization and their auditors
- To monitor the performance of the auditing organizations and their auditors
- To improve consistency between auditing organizations and their auditors

29 30

7.4 User needs for the manufacturer and/or auditee

31 32

33

34

- The manufacturer and/or auditee use audit reports:
- To provide a record of the auditing activities and audit scope
- To provide evidence of compliance to regulatory requirements
- To learn about the status of the quality management system (including nonconformities)
- To get feedback for further improvement of the quality management system
- To prepare for the next audit
- To provide an audit history
- To trend compliance history
- To provide evidence of compliance to regulatory authorities/auditing organizations as part of product registration/license activities
- To carry out necessary corrective and preventive actions

27 June 2006 Seite 8 von 12

Part 3: Regulatory Audit Report

SG4 (PD1) N33 R13 - Study Group 4 - Proposed Document

8.0 Main points for a Regulatory Audit Report

3 The auditing organization/regulator may adopt reporting procedures that suit its needs. 4 The items contained in this chapter should be included in the audit report as a minimum 5 requirement.

The report shall be typed and may be in a format that can be stored and transferred electronically.

8 9 10

11

6 7

1

2

Note: The language of the report should be agreed upon between the auditee and the auditing organization prior to the start of the audit. In many cases, the ultimate use of the report will dictate the language of the report.

12 13 14

8.1 Data concerning auditee

15 16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

- 8.1.1 Auditee's name, address, phone #, fax #, e-mail
- 8.1.2 Company's ID # for each regulatory authority covered by this audit (if applicable)
- 8.1.3 Description of the auditee (e.g., approximate number of employees covered by the audit scope, organization chart, hours of operations and any seasonal variations, percent of export). If a facility other than the main site of the auditee exists and/or is being audited, then the relationship of that site to the main site should be given.
- 8.1.4 The corporate identity and company names of the manufacturer
- 8.1.5 Status of any relevant certification
- 8.1.6 Products scope/product families and classifications covered by the audit (using an applicable nomenclature system, e.g. Global Medical Device Nomenclature (GMDN), where feasible)
- 8.1.7 Name, location and activity of critical suppliers, if applicable
- 8.1.8 Management representative for the quality management system
- 8.1.9 Date of previous audit, name of last auditor and result, if applicable
- 8.1.10 Additional information regarding compliance history of the auditee, if relevant
- 8.1.11 Auditee's representative or key contact person(s) for
 - a. Arranging the audit
 - b. Receiving the final audit report
 - c. Receiving regulatory correspondence

36 37 38

8.2 Data concerning audit

39 40

41

42

43

44

- 8.2.1 Type of audit (e.g. initial, surveillance, special audit)
- 8.2.2 Audit criteria against which the audit was conducted (regulation(s) and standard(s))
- 8.2.3 On-site audit dates and time
- 8.2.4 Total audit time (auditor days)

27 June 2006 Seite 9 von 12

Part 3: Regulatory Audit Report SG4 (PD1) N33 R13 – Study Group 4 – Proposed Document

1	8.2.5 Identification of the auditing organization and audit team members (including					
2	technical experts) and their roles and responsibilities					
3	8.2.6 Interpreter, if applicable					
4	8.2.7 Observer(s) and their organization, if applicable					
5	8.2.8 List of documentation reviewed prior to the audit, including					
6 7	document identification and revision status					
8	8.3 Audit trail					
9	0.5 Audit tran					
10	8.3.1 Description of activities covered during the audit. Write a summary description					
11	of the key elements covered under the following subsystems:					
12	 Management 					
13	 Design and Development (describe the project(s) reviewed) 					
14	Product Documentation					
15	 Production and Process Controls (describe product and process/es reviewed) 					
16	 Corrective and Preventive Actions (report data sources available for review, 					
17	and which ones were reviewed)					
18	 Purchasing Controls 					
19	Documentation and Records					
20	Customer Related Processes					
21	Note: These are the subsystems in GHTF/SG4/N30, Guidelines for Regulatory					
22	Auditing of Quality Management Systems of Medical Device Manufacturers –					
23	Part 2: Regulatory Auditing Strategy.					
24	Ture In the guidality Traditions & State By.					
25	The subsystem summary(ies) may include:					
26	 Areas of the site visited (e.g., incoming inspection, manufacturing areas, 					
27	quality control laboratories, etc) and, where relevant, persons interviewed					
28	 Activities and processes evaluated, including the reason for their selection 					
29	Documents reviewed, including document number, revision etc					
30	• Specific references to records reviewed, e.g., complaints files, batch					
31	records etc					
32	 Specific references to products reviewed, e.g., work in progress, 					
33	components etc					
34	• Statement concerning compliance with the standard or regulation(s) being					
35	audited, e.g,					
36	o conforming					
37	o comments for improvement, if applicable					
38	o nonconformity (including major nonconformities)					
39	Note: If a comment for improvement is recorded in the audit report which does					
40	not lead to a nonconformity, it should be clear why a nonconformity was not					
41	raised.					
42						

27 June 2006 Seite 10 von 12

43

44

If a checklist without any further information is used to demonstrate coverage in

a particular area then this should be supported in the written narrative report.

Part 3: Regulatory Audit Report SG4 (PD1) N33 R13 – Study Group 4 – Proposed Document

1	8.3.2 Description of recalls, product removals, or product replacements since the last
2 3	audit, if applicable 8.3.3 Description of major changes to products or significant changes to processes,
4 5	organizational structure, ownership, key personnel and quality management system since the last audit
6	8.3.4 Description of any follow-up on specific complaints or adverse event reports, if
7 8	applicable 8.3.5 Identification of any requested information that was refused
9	8.3.6 Details of each nonconformity (referenced to relevant regulation or standard) and relative severity with respect to regulatory requirements
1	8.3.7 Details of corrective action(s) taken during the audit
2 3	Note: When a nonconformity is found, a record of this should be completed even if the auditee corrects the nonconformity during the audit.
4 5	8.3.8 Verification of effective implementation of corrective action(s) from previous audit
6	8.3.9 Description of any items or comments for improvement not given in list of nonconformities, if applicable
7 8	8.3.10 The proposed time frame for responding to the nonconformities, if applicable
9	8.3.11 Follow-up items for the next audit
20	8.3.12 Details of information provided during the closeout meeting, including
21	auditees responses
	8.3.13 Unresolved diverging opinions between audit team and auditee
23	The state of the s
22 23 24	8.4 Conclusion
25	
26	8.4.1 Summary and conclusions regarding the conformity of the
27	auditee's quality management system with the audit criteria
28	8.4.2 Auditor's recommendation to the auditing organization (as applicable):
29	a) Follow up action(s) including proposed time schedule(s)
30	b) For the initial or continued certification
31 32	9.5 Cignoture and dating of variout
33	8.5 Signature and dating of report
34	8.5.1 Date of the audit report
35	8.5.2 Lead auditor, auditor(s) names, titles and organizations (signature and/or stamp
36	of auditors on report)
37	of additions on report)
38	8.6 Attachments (that could be used to support the content of the report)
39	Audit plan(s) (if applicable)
10	 Attendance sheet for opening and closing meetings (if applicable)
ļ1	Relevant auditing organization documents
 12	 Evidence available to support the nonconformities
13	Checklist used by the auditor

27 June 2006 Seite 11 von 12

Nonconformity reports if issued separately

44







History file:

5

6

7

Development of SG 4 / N 33 "Guidelines for Regulatory Auditing of Quality Systems of Medical Device Manufacturers – Part 3: Regulatory Audit Reports"

		rait 5. Regulatory Addit Reports
Date	SG 4 N	Tasks
d-m-y	33	
1.3.2003	N 6 R2	Audit reports: User needs
		Basis for N 33
24.9.2003	N 6 R3	At meeting in Bern, Switzerland, updating the main
		requirements for N 33
22.12.2003	R 1	Structure of N 33
Dec 2003 -	N 330 – N	Development of requirements for N 33 for Audit Report
March 2005	339	Matrix
4.2.2004	R 4	After written comments draft for Atlanta meeting
3.5.2004	R 5	After written comments draft for Tokyo meeting
21.9.2004	R 6	At Canberra meeting revision of first half of document
7.4.2005	R 7	Revision of N 33 incl. new chapter 7
1.9.2005	R 8	Total revision of chapter 7 for Gaithersburg meeting
15.9.2005	R 9	Working Draft after Gaithersburg meeting incl. changes
15.9.2005	R 9a	Clean version of WD
16.11.2005	R 10	Working Draft after Luebeck meeting incl. changes
24.11.2005	R 10a	Clean version of WD incl. template
16.2.2006	R 11	In Taipei: Implementing 4 comments (partly extensive!)
22.3.2006	R 12	Working Draft after Taipei
3.4.2006	R 12	Proposed Document, but not sent to SC (ident. With
		22.3.)
28.6.2006	R 13	Final corrections, Proposed Doc, will be sent to SC for comments

Status 28.6.2006 Dierk Bellwinkel

11 12 13

10

8 9

27 June 2006 Seite 12 von 12